RxDoctor Payments Data

Eric Giesler, MD

Urology · Austin, TXNPI 1215068242

Payments from drug & device makers

$31,653in general payments, 2019–2025

Across 436 payments — averaging $72.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EDAP Technomed Inc$13K
  • Intuitive Surgical$6K
  • Johnson & Johnson$2K
  • Neotract Inc.$1K
  • Astellas Pharma US Inc$1K
  • AbbVie$627
  • plus $7K from 47 others

What the payments were for

  • Consulting fees$11,92638%
  • Travel & lodging$6582%
  • Food & beverage$12,70940%
  • Education$6,35920%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,653 in reported general payments places this provider in the 85th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$336,399
Medicare patients
793
Services billed
5,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide115$1,627,944
OrgovyxRelugolix288$732,432
XtandiEnzalutamide46$654,387
Abiraterone Acetate168$372,849
NubeqaDarolutamide16$144,014
MyrbetriqMirabegron70$69,726
GemtesaVibegron49$38,729
Mirabegron ErMirabegron18$11,801
Dutasteride196$6,461
Tamsulosin Hcl365$5,157
Trospium Chloride64$4,167
Solifenacin Succinate96$3,301
Alfuzosin Hcl ErAlfuzosin Hcl176$3,248
Methenamine Hippurate25$3,070
Testosterone Cypionate29$1,782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$2,440$1,627,944115 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$233$771,161337 claims
Astellas Pharma US IncXtandi, Myrbetriq$1,019$724,113116 claims
BayerNubeqa$363$144,01416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 878 urology providers in Texas.

Other urology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →